NEW YORK, May 27 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC Bulletin Board: IYXI), an emerging specialty pharmaceutical company with a focus on niche drug delivery technologies and products, announced today that Ulrich Bartke, Ph.D. will be joining the company on June 1, 2004 in the newly established, senior management position of Vice President Global Sales & Marketing. "We are very pleased to have a person with Mr. Bartke's extensive and highly successful pharmaceutical business experience join Inyx," said Dr. Jack Kachkar, Inyx Chairman & CEO. "Mr. Bartke's appointment is part of Inyx's evolution into an integrated specialty pharmaceutical company. Through his direction and initiatives, Inyx's sales and marketing efforts should be significantly enhanced. "Initially, Mr. Bartke will focus on building Inyx's contract manufacturing revenues and increasing the utilization of production capacity, with the objective to increase sales and profitability," Dr. Kachkar informed. "Additionally, he will be cultivating strategic marketing relationships with key clients to handle the distribution of Inyx's own proprietary products, which we are now developing and plan to start to introduce in early 2005." "I am very pleased to be joining Inyx," said Mr. Bartke. "Inyx has niche aerosol pharmaceutical development and production expertise that is needed in the marketplace today, particularly the proven ability to develop and produce non-ozone-depleting aerosol products. I am looking forward to assisting in the growth of Inyx's business." Mr. Bartke will be based initially at the company's development and production center located in Cheshire, England, operated under its wholly owned subsidiary INyX Pharma Limited. He will be directing the company's sales and marketing activities around the world, including in North America, Latin and South America and Asia as well as Europe. Ulrich Bartke, Ph.D. From 2001 to 2003, Mr. Bartke served as Vice President Global Sales & Marketing of PowderJect Pharmaceuticals Plc, where he directed sales growth from approximately $40 million to in excess of $290 million during his two- year tenure. In June 2003, PowderJect, at the time a publicly owned company traded on the London Stock Exchange, was acquired by Chiron Corporation. Following this acquisition, Mr. Bartke became a consultant to the pharmaceutical industry, focusing on U.S. and European markets. Mr. Bartke began his professional career and served for 17 years, from 1984 to 2001, with GlaxoSmithKline companies in a number of different executive capacities. He started out in manufacturing management positions before moving into several marketing directorships at SmithKline Beecham Pharmaceuticals. In his last position, he served as Therapy Area Director, Vaccines, for GSK Pharmaceuticals Europe. Mr. Bartke holds a BSc in Pharmacy and a Ph.D. in Pharmaceutical Chemistry from the University of Berlin. About Inyx Inyx, Inc. is an emerging specialty pharmaceutical company with niche aerosol drug delivery technologies and products. Inyx focuses its expertise on contract manufacturing of prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services to the international healthcare market. In addition, Inyx is developing its own proprietary products to be marketed by selected clients and strategic partners. The company's operations are conducted through its wholly owned subsidiary, INyX Pharma Limited, with a focus on niche products and technologies for the treatment of respiratory, allergy, dermatological and topical conditions. INyX Pharma's client base comprises large ethical pharmaceutical corporations, branded generic companies and biotechnology firms. The company develops and manufactures for a majority of global markets, including: North America, Europe, Latin America and the Middle East. INyX Pharma's R&D and production facilities are in Runcorn, near Manchester, England. Another wholly owned subsidiary, Inyx Canada, Inc. based in Toronto, provides business development and support services. Inyx, Inc.'s corporate offices are in New York City. Safe Harbor Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. For more information, please contact: Jay M. Green, Executive VP Inyx, Inc. 212-838-1111 email@example.com
SOURCE Inyx, Inc.